By Bethany Wales Biotech firm Reneuron Group has become the latest company to exit from the London Stock Exchange’s AIM as it continues to fight for its life after entering administration. The Welsh company, which was first floated on London’s junior market in 2005, said it did not believe it would be able to raise enough funds to resume public trading given the “additional costs and regulatory obligations” associated with the AIM market. The announcement follows months of difficulty for the stem cell technology business, which entered administration in March and has since revealed plans to ma…